10-Q: American Well Q1 2026 Earnings: Revenue Decline, Cost Reductions

American Well Corporation reported a 18% revenue decrease in Q1 2026 compared to the prior year, driven by lower subscription and other revenues, alongside significant cost-cutting measures.

Summary

• Revenue for the first quarter of 2026 was $54.9 million, an 18% decrease from $66.8 million in the same period of 2025.
• The decline in revenue was primarily attributed to a $7.3 million decrease in subscription revenue and a $6.9 million decrease in other revenue (professional services).
• Visit revenue saw an increase of $2.3 million, driven by a shift in visit mix towards special program visits.
• Total costs and operating expenses decreased by 26% to $72.3 million from $97.2 million in Q1 2025, largely due to significant reductions in R&D, sales & marketing, and G&A expenses.
• The company reported a net loss of $10.3 million for the quarter, an improvement from a net loss of $18.4 million in Q1 2025.
• Adjusted EBITDA improved to a loss of $3.1 million from a loss of $12.2 million in the prior year's quarter.
• Cash and cash equivalents stood at $179.2 million as of March 31, 2026, with the company believing it has sufficient liquidity for at least the next 12 months.
• The company incurred $4.5 million in severance and strategic transformation costs in Q1 2026, including a $3.4 million impairment charge for its corporate headquarters lease.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, despite improvements in cost management and a reduced net loss. The company's path to profitability remains uncertain.

Positives

• Net loss improved significantly to $10.3 million from $18.7 million in the prior year's quarter.
• Adjusted EBITDA loss narrowed substantially to $3.1 million from $12.2 million.
• Total costs and operating expenses were reduced by 26% year-over-year, indicating successful cost management.
• Research and development expenses decreased by 44%, sales and marketing by 38%, and general and administrative expenses by 24%, reflecting strategic cost optimization.
• The company maintains a strong cash position of $179.2 million, providing ample liquidity.
• Visit revenue increased by $2.3 million, showing resilience in core service utilization.

Negatives

• Total revenue decreased by 18% to $54.9 million, primarily due to lower subscription and other revenues.
• Subscription revenue declined by $7.3 million, impacting a key recurring revenue stream.
• Other revenue, largely from professional services, decreased by $6.9 million.
• The company continues to operate at a net loss, with an accumulated deficit of $2.1 billion.
• Significant severance and strategic transformation costs were incurred, including a $3.4 million impairment charge for the corporate headquarters.

Risks

• The company has a history of losses and may not achieve profitability.
• There is a risk of losing business from its limited number of significant clients.
• Increased competition in the digital care market.
• Changes in healthcare laws and regulations could impact operations.
• Potential for significant liability from cybersecurity breaches or failure to comply with privacy regulations.
• Slower than expected growth in patient adoption of digital care.
• Inability to grow its base of affiliated and non-affiliated providers.
• The continuation of the Defense Health Agency relationship beyond July 2026 with comparable financial terms is uncertain.

Future Outlook

The company believes its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months. Future capital requirements will depend on growth rate, contract renewals, consultation volume, product development spending, sales and marketing expansion, new service offerings, and market acceptance of digital care. The company may seek additional equity or debt financing in the future, and failure to secure it could adversely affect its business.

Management Comments

• The Company has demonstrated the strength of our revenue as a direct result of the increasing acceptance of digital care, our penetration of the market, and the successful launch of new and expanded products that enable broadened applications for care delivered virtually.
• We believe increased spending in prior years was a temporary investment to accelerate development of a more scalable and economically beneficial solution that will properly position the Company to benefit in the long term and have seen decline during the year as we return to normal levels of spend in future periods.
• We expect sales and marketing expense to remain consistent in future periods.
• We expect our general and administrative expenses to remain relatively flat in future periods.
• We divested the APC Business as it was determined the offering no longer fit our goals around profitability and growth. Streamlining our service offerings will enable us to focus our resources on the Amwell Platform, strategic customers, and our path to profitability.

Industry Context

StockSavvy.ai notes that American Well's Q1 2026 results reflect ongoing industry trends in digital health, including a shift in revenue mix and a strong focus on cost optimization. While overall revenue declined, the improvement in Adjusted EBITDA and the strategic reduction in operating expenses suggest a company actively managing its path towards profitability in a competitive landscape.

Comparison to Industry Standards

• The decline in subscription revenue is a concern, as recurring revenue is a key indicator of stability and predictability in the SaaS industry. Competitors like Teladoc Health also face challenges in subscriber growth and profitability.
• The significant reduction in R&D and Sales & Marketing expenses, while improving short-term profitability, could impact long-term innovation and market share capture if not carefully managed. Companies like Amwell's competitors are also investing heavily in platform development and market expansion.
• The company's focus on a hybrid care model aligns with broader industry trends, where integrated care delivery is becoming paramount. However, the execution and adoption of these models vary across the sector.

Legal Proceedings

• The company is not presently a party to any legal proceedings that management expects to have a material adverse effect on its business, financial condition, results of operations, or cash flows.
• A legal accrual of $8.65 million is noted, with $5.2 million related to one specific case.

Related Party Transactions

• Transactions with Cleveland Clinic, where a board member is an executive advisor, include deferred revenue of $65,000 (March 31, 2026) and amounts due of $359,000 (March 31, 2026). Revenue recognized from Cleveland Clinic was $249,000 for Q1 2026.
• The joint venture CCAW, JV LLC with Cleveland Clinic is undergoing liquidation. Amounts due from CCAW, JV LLC were $460,000 (March 31, 2026). Revenue recognized from CCAW, JV LLC was $331,000 for Q1 2026.

Stakeholder Impact

• Shareholders: Continued net losses and revenue decline may impact stock valuation, though cost reductions and improved EBITDA offer some positive signals.
• Employees: Headcount reductions in R&D, sales & marketing, and G&A indicate potential workforce impacts.
• Customers: The company's focus on its platform and strategic customers aims to maintain and deepen relationships.
• Creditors: The company has no debt, reducing immediate creditor risk.

Next Steps

• Continue to focus resources on the Amwell Platform, strategic customers, and the path to profitability.
• Evaluate potential strategic transformation actions to align cost structure with revenue profile.
• Monitor the continuation of the Defense Health Agency relationship beyond July 2026.

Key Dates

Recommendation

The company shows progress in cost management and reducing its net loss, which is positive. However, the significant decline in revenue, particularly subscription revenue, raises concerns about future growth. The strong cash position provides a buffer, but the path to sustainable profitability is not yet clear. A 'hold' recommendation reflects a wait-and-see approach, awaiting evidence of revenue stabilization and growth before considering a more positive stance.

Keywords

American Well, Amwell, 10-Q, Quarterly Report, Digital Health, Telehealth, Virtual Care, Healthcare Technology, Financial Results, Revenue, Net Loss, Adjusted EBITDA